Intracellular signaling prevents effective blockade of oncogenic gp130 mutants …7thSpace Interactive (press release)As a consequence, Stat3 activation through CAgp130 cannot be inhibited by neutralizing gp130 antibodies but through overexpression of …
Ludwig And Agenus To Begin Development Of Promising AntibodiesBioResearch Online (press release)Ludwig Cancer Research and Agenus Inc. announced that the companies are advancing three selected monoclonal antibody checkpoint modulators (CPMs) into precl…
Clinical Oncology News |
Obinutuzumab Superior to Rituximab in CLL
Clinical Oncology News New Orleans—In previously untreated patients with chronic lymphocytic leukemia and comorbidities, the novel CD20-targeted monoclonal antibody obinutuzumab is more active than rituximab, according to results of a Phase III trial that paired both with … |
Bioscience TechnologyEnterovirus Monoclonal AntibodiesBioscience TechnologyViroStat Enterovirus Monoclonal Antibodies Enteroviruses are a diverse group of RNA viruses including Poliovirus, Rhinoviruses, Coxsackie A & B viruses, and Echoviruses. Mos…
Pharmacy Practice News |
Obinutuzumab Superior to Rituximab in CLL
Pharmacy Practice News New Orleans—In previously untreated patients with chronic lymphocytic leukemia and comorbidities, the novel CD20-targeted monoclonal antibody obinutuzumab is more active than rituximab, according to results of a Phase III trial that paired both with … |
Drug Discovery & Development |
Agenus, Ludwig to Advance Antibodies into Development
Drug Discovery & Development Ludwig Cancer Research and Agenus Inc. announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 … |
|
Research and Markets: Investigation Report on China Rituximab Market, 2009 …
Business Wire (press release) Rituximab (trade names “”MabThera”” by Roche, “”Rituxan”” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. |
|
Researchers at CAPRISA discovered potent antibodies to neutralize HIV
Jagran Josh Researchers studied how a South African woman’s body referred to as CAPRISA 256 (abbreviated to CAP256) responded to her HIV infection by making potent antibodies. These potent antibodies are also called as neutralizing antibodies because of their … |
|
BMO Capital Upgrades Biogen (BIIB) to Outperform
StreetInsider.com (subscription) “With additional opportunities over the next 12 months for proof-of- concept with anti-LINGO for remyelination, TYSABRI in secondary progressive MS (SPMS), daclizumab in relapsing and remitting MS (RRMS), BIIB037 in Alzheimer’s, STX-100 in idiopathic … |
Cabinet Welcomes Discovery of Potent HIV AntibodiesAllAfrica.comCabinet has welcomed the announcement made by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Consortium on the discovery of potent new HIV antibodies that could ne…